Data cast more doubt on Avastin's benefit in older NSCLC patients
This article was originally published in Scrip
Roche/Genetech's Avastin (bevacizumab) may not prolong life in older patients with non-small cell lung cancer and should not be considered standard of care in this context, say researchers in a new study published in the Journal of the American Medical Association.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.